FDA approves KALYDECO for treatment of eligible infants with cystic fibrosis
KALYDECO is already approved in the U.S., Canada and EU for the treatment of CF in patients ages 12 months and older. “Today’s approval for KALYDECO allows physicians
The 20-acre site will significantly expand Kite’s ability to manufacture a variety of chimeric antigen receptor T (CAR T) therapies, including Yescarta (axicabtagene ciloleucel), Kite’s first commercially available
Solifenacin Succinate Tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Overactive bladder (OAB) is
Phyton Biotech is the world’s leading manufacturer of paclitaxel active pharmaceutical ingredient (API), utilizing its prorprietary PCF technology process. Under the strategic partnership with AqVida, Phyton Biotech will
iPSCs can be derived from adult human tissue cells yet share the developmental potentials of embryonic stem cells. Currently Japan has 6 ongoing clinical trials utilizing this technology,
The intended clinical trial will be a proof-of-concept study combining Novo Nordisk’s semaglutide (GLP-1 analogue) and Gilead’s cilofexor (FXR agonist) and firsocostat (ACC inhibitor) for the treatment of